Payne Jennifer L, Meltzer-Brody Samantha
Women's Mood Disorders Program, Johns Hopkins School of Medicine, 550 N. Broadway, Baltimore, MD, USA.
Clin Obstet Gynecol. 2009 Sep;52(3):469-82. doi: 10.1097/GRF.0b013e3181b52e20.
The treatment of depression during pregnancy is both a common and complex clinical challenge. The decision to expose the fetus to antidepressant medication during pregnancy must be weighed against the risks of untreated maternal depression to both mother and fetus. Maternal depression during pregnancy has been associated with increased rates of preterm birth and maternal substance use. The safety of antidepressant use during pregnancy seems to be largely reassuring but there remain 2 areas of controversy including neonatal withdrawal syndrome and primary pulmonary hypertension of the newborn. Individualized treatment recommendations based on the patient's history are essential to optimize outcomes.
孕期抑郁症的治疗是一项常见且复杂的临床挑战。在孕期让胎儿接触抗抑郁药物的决定,必须与未治疗的母亲抑郁症对母亲和胎儿的风险相权衡。孕期母亲抑郁与早产率增加及母亲物质使用有关。孕期使用抗抑郁药物的安全性在很大程度上似乎是令人放心的,但仍存在两个有争议的领域,包括新生儿戒断综合征和新生儿原发性肺动脉高压。根据患者病史制定个体化的治疗建议对于优化治疗效果至关重要。